| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/03/2001 | US6255296 Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
| 07/03/2001 | US6255295 Mixture of glucosamine and pentosan polysulfate |
| 07/03/2001 | US6255290 Reducing sensitivity to skin cancer; topical administering of nucleotide |
| 07/03/2001 | US6255281 Complexing uteroglobin to fibronectin |
| 07/03/2001 | US6255277 Localized use of nitric oxide-adducts to prevent internal tissue damage |
| 07/03/2001 | US6255091 Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions |
| 07/03/2001 | US6255072 Nucleotide sequences coding proteolytic polypeptide; for use as diagnostic tool; for the prevention of bacterial infection |
| 07/03/2001 | US6255046 Drug screening of enzyme inhibitors by expressing enzyme or kinase domain, purifying, isolating, adding test compound and fructose 6-phosphate, and measuring formation of fructose 2,6 bisphosphate product; reduction indicates candidate |
| 07/03/2001 | US6254893 Calcium-based ophthalmic composition including a hydrophobic carrier, such as petrolatum, and a calcium salt, sufficiently viscous to prevent dripping or running after application to the skin adjacent the eyelids |
| 07/03/2001 | US6254585 Surgical irrigation solution and method for inhibition of pain and inflammation |
| 07/03/2001 | CA2132512C Bioadhesive pharmaceutical composition used for the controlled release of active ingredient |
| 07/03/2001 | CA2077641C Aqueous suspension preparation for injection, method for producing the same and use thereof for producing pain relief |
| 06/29/2001 | CA2329576A1 Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-ht1d receptor selective antagonists |
| 06/29/2001 | CA2293913A1 Treatment of necrotizing infections |
| 06/28/2001 | WO2001046700A2 Sodium channels as targets for amyloid beta |
| 06/28/2001 | WO2001046699A1 INHIBITION OF βARRESTIN MEDIATED EFFECTS PROLONGS AND POTENTIATES OPIOID RECEPTOR-MEDIATED ANALGESIA |
| 06/28/2001 | WO2001046698A2 Tethered ligands and methods of use |
| 06/28/2001 | WO2001046455A2 Survivin promotion of angiogenesis |
| 06/28/2001 | WO2001046443A2 Proteases |
| 06/28/2001 | WO2001046397A2 Human kinases |
| 06/28/2001 | WO2001046394A2 Mammalian protein phosphatases |
| 06/28/2001 | WO2001046392A2 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | WO2001046383A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 06/28/2001 | WO2001046261A1 Method for treating inflammation |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046256A2 Vesicle trafficking proteins |
| 06/28/2001 | WO2001046223A1 Compounds and use thereof to modify transport across cell membranes |
| 06/28/2001 | WO2001046206A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046205A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046204A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | WO2001046203A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046199A1 Methods and compounds for inhibiting mrp1 |
| 06/28/2001 | WO2001046195A1 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| 06/28/2001 | WO2001046191A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046151A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 06/28/2001 | WO2001046140A1 Ep4 receptor selective agonists in the treatment of osteoporosis |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046114A1 Method for making hbed |
| 06/28/2001 | WO2001045836A2 Molecules derived from mechanism based drug design |
| 06/28/2001 | WO2001045752A1 Interventions to mimic the effects of calorie restriction |
| 06/28/2001 | WO2001045749A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | WO2001045740A2 Compositions and methods for treatment of breast cancer |
| 06/28/2001 | WO2001045730A2 Tweak receptor |
| 06/28/2001 | WO2001045727A2 Stabilized veterinary compositions comprising more than one antiviral agent |
| 06/28/2001 | WO2001045717A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | WO2001045716A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor |
| 06/28/2001 | WO2001045715A2 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 06/28/2001 | WO2001045714A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045713A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
| 06/28/2001 | WO2001045708A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| 06/28/2001 | WO2001045707A1 Inhibitors of prenyl-protein transferase |
| 06/28/2001 | WO2001045705A1 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 06/28/2001 | WO2001045704A1 Inhibitors of prenyl-protein transferase |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045701A1 Natural extracted and synthetic antioxidant compositions |
| 06/28/2001 | WO2001045696A1 N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid in iron chelating therapy |
| 06/28/2001 | WO2001045691A2 Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| 06/28/2001 | WO2001045690A2 Use of bvdu for inhibiting the growth of hyperproliferative cells |
| 06/28/2001 | WO2001045686A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045685A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045684A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045683A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045682A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045678A2 Medicament, a method for its production and the use thereof |
| 06/28/2001 | WO2001045677A1 Process for producing nanometer particles by fluid bed spray-drying |
| 06/28/2001 | WO2001045676A2 Extended release oral dosage composition |
| 06/28/2001 | WO2001045674A1 Process for producing nanometer particles by fluid bed spray-drying |
| 06/28/2001 | WO2001045668A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 06/28/2001 | WO2001045667A2 Water-soluble powders for oral solution and use thereof |
| 06/28/2001 | WO2001045664A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/28/2001 | WO2001045645A1 Chitosan biopolymer for the topical delivery of active agents |
| 06/28/2001 | WO2001045641A2 Inhibitors of thrombin induced platelet aggregation |
| 06/28/2001 | WO2001045599A1 Tissue sensitizing compounds for females with methods and apparatus for the delivery of these compounds |
| 06/28/2001 | WO2001045585A1 Dental prosthesis with means for the release of active substances |
| 06/28/2001 | WO2001045509A1 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
| 06/28/2001 | WO2001002561A3 Mammalian calcium channels and related probes, cell lines and methods |
| 06/28/2001 | WO2000078322A3 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 06/28/2001 | WO2000075305A3 Candida albicans genes and proteins coded by said genes |
| 06/28/2001 | WO2000073331A3 Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| 06/28/2001 | WO2000072855A3 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 06/28/2001 | WO2000071741A3 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 06/28/2001 | WO2000070351A3 Protein-protein interactions and methods for identifying them |
| 06/28/2001 | WO2000070049A3 Extracellular signaling molecules |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000067773A3 Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
| 06/28/2001 | WO2000066708A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/28/2001 | WO2000061180A3 Products and methods for treating ptp lar related diseases |
| 06/28/2001 | WO2000044774A3 Inhibition of stat3 signal transduction for human cancer therapy |
| 06/28/2001 | WO2000042987A8 Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections |
| 06/28/2001 | WO1999000112A8 Sucralfate-containing composition and process for the preparation thereof |
| 06/28/2001 | WO1997046686A3 Tumor necrosis factor-related polypeptide |
| 06/28/2001 | US20010005729 Absorption rate of a pharmaceutically active amine such as pseudoephedrine is improved when formulated with an acidic nonsteroidal antiinflammatory drug such as ibuprofen in a liquid medium; includes dosage for children |
| 06/28/2001 | US20010005714 Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
| 06/28/2001 | US20010005712 Parenterally administering Product R, a peptide-nucleic acid preparation, in combination with one or more antiviral agents useful for treating AIDS or HIV infections including HIV protease inhibitors and nucleosides |
| 06/28/2001 | DE19961897A1 Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen Using a film coating as taste coating of pharmaceutical dosage forms |
| 06/28/2001 | DE19959913A1 Acetylsalicylsäure enthaltendes transdermales System zur Behandlung von Migräne Aspirin-containing transdermal system for the treatment of migraine |
| 06/28/2001 | DE19959049A1 Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen Combination of compounds, which inhibit the biological effects of TNF-alpha and CD95L |
| 06/28/2001 | CA2395513A1 Methods and compounds for inhibiting mrp1 |
| 06/28/2001 | CA2395471A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |